Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: Results from the PHOENIX 2 study through 5 years of follow-up

British Journal of Dermatology

Volumn 172, Issue 5, 2015, Pages 1371-1383

  Langley, R G ^a   Lebwohl, M ^b   Krueger, G G ^c   Szapary, P O ^d   Wasfi, Y ^d   Chan, D ^d   Hsu, M C ^d   You, Y ^d   Poulin, Y ^e   Korman, N ^f   Prinz, J C ^g   Reich, K ^h  

^a DALHOUSIE UNIVERSITY   (Canada)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^e UNIVERSITÉ LAVAL   (Canada)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^g UNIVERSITY OF MUNICH   (Germany)

^h Dermatologikum Hamburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

USTEKINUMAB; DERMATOLOGICAL AGENT;

ADULT; ARTICLE; BODY SURFACE; CELLULITIS; CEREBROVASCULAR ACCIDENT; CHOLECYSTITIS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DIVERTICULITIS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NON MELANOMA SKIN CANCER; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RANDOMIZED CONTROLLED TRIAL; SERUM SICKNESS; SINGLE DRUG DOSE; TREATMENT RESPONSE; BODY WEIGHT; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME;

BODY WEIGHT; CROSS-OVER STUDIES; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME; USTEKINUMAB;

EID: 84929092448     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13469     Document Type: Article

References (14)

1. Leonardi CL, Powers JL, Matheson RT, et al,. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-22.
2. Lebwohl M, Tyring SK, Hamilton TK, et al,. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004-13.
3. Menter A, Tyring SK, Gordon K, et al,. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15.
4. Leonardi CL, Kimball AB, Papp KA, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74.
5. Papp KA, Langley RG, Lebwohl M, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84.
6. Kimball AB, Papp KA, Wasfi Y, et al,. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2013; 27: 1535-45.
7. Gordon K, Papp K, Poulin Y, et al,. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol 2012; 66: 241-51.
8. Brezinski EA, Armstrong AW,. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS One 2012; 7: e33486.
9. Fredriksson T, Pettersson U,. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
10. Geng D, Shankar G, Schantz A, et al,. Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. J Pharm Biomed Anal 2005; 39: 364-75.
11. Puig L,. Shortcomings of PASI75 and practical calculation of PASI area component. J Am Acad Dermatol 2013; 68: 180-1.
12. Puig L, Bordas X, Carrascosa JM,. Consensus document on the evaluation and treatment of moderate to severe psoriasis. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr 2009; 100: 277-86.
13. Augustin M, Alvaro-Gracia JM, Bagot M, et al,. A framework for improving the quality of care for people with psoriasis. J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 4): 1-16.
14. Papp KA, Griffiths CEM, Gordon K, et al,. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013; 168: 844-54.